DIAGENIC

for early disease detection

2nd Quarter 2012
New CEO – R&D Excellence
Progress in Alzheimer's and Parkinson's Disease

Henrik Lund MD PhD, CEO
Magnus Sjögren, MD PhD, CMO
Ruben Ekbråten, CFO



Disclaimer

This document (the "Presentation") has been prepared by DiaGenic ASA (the "Company") exclusively for information purposes. Neither this Presentation nor any copy of it nor the information contained herein is being issued, and nor may this Presentation nor any copy of it nor the information contained herein be distributed directly or indirectly to or into, any jurisdiction in which such distribution would be unlawful or not appropriate. Recipients of the Presentation shall not reproduce, redistribute or pass on, in whole or in part, the Presentation or any of its content to any other person. The Presentation does not constitute, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, and are sometimes identified by the words "believes", expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that are expressed or implied by statements and information in the Presentation, including, among others, risks or uncertainties associated with the Company's business, segments, development, growth management, financing, market acceptance and relations with customers, and, more generally, general economic and business conditions, changes in domestic and foreign laws and regulations, taxes, changes in competition and pricing environments, and fluctuations in currency exchange rates and interest rates. None of the Company or any of its subsidiaries or any such person's directors, employees or advisors provide any assurance that the assumptions underlying forward-looking statements expressed in this Presentation are free from errors nor does any of them accept any responsibility for the future accuracy of such forward-looking statements.

The information contained in this Presentation has not been independently verified. No representation or warranty (express or implied) is made as to the accuracy or completeness of any information contained herein, and it should not be relied upon as such. None of the Company or its subsidiaries or any such person's directors, employees or advisors shall have any liability whatsoever arising directly or indirectly from the use of this Presentation. By reading the Presentation, or attending any oral presentation held in relation thereto, you acknowledge that you will be solely responsible for your own assessment of the Company, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. The content of this Presentation are not to be construed as legal, business, investment or tax advice. Each recipient should consult with its own professional advisors for any such matters and advice.

No action has been taken to allow the distribution of this Presentation in any jurisdictions other than Norway. The Presentation has not been reviewed or registered with, or approved by, any public authority, stock exchange or regulated market. The distribution of this Presentation, as well as any subscription, purchase, sale or transfer of securities issued by the Company, may be restricted by law in certain jurisdictions, and persons into whose possession this Presentation comes are required by the Company to inform themselves about and comply with any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction. None of the Company or its subsidiary undertakings or any such person's directors, employees or advisors shall have any responsibility for any such violations.

THIS PRESENTATION AND THE INFORMATION CONTAINED HEREIN DO NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND ARE NOT FOR PUBLICATION OR DISTRIBUTION TO U.S. PERSONS (WITHIN THE MEANING OF REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")). THE SECURITIES OF THE COMPANY HAVE NOT AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO U.S. PERSONS, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.

IN RELATION TO THE UNITED KINGDOM, THE PRESENTATION IS STRICTLY CONFIDENTIAL AND IS ONLY DIRECTED AT PERSONS WHO FALL WITHIN THE MEANING OF ARTICLE 19 (INVESTMENT PROFESSIONALS) AND 49 (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 OR WHO ARE PERSONS TO WHOM THE PRESENTATION MAY OTHERWISE LAWFULLY BE DISTRIBUTED.

There may have been changes in matters which affect the Company subsequent to the date of this Presentation. Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, except as required by law, to update or correct any information included in this Presentation.

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of the Norwegian courts.

Agenda Q2 2012 presentation

- New CEO in DiaGenic – Paul de Potocki appointed - change of management September 17th
- DiaGenic reaches 82% accuracy milestones for ADtect product improvement – results from AAIC
- Clinical phase of GE Healthcare collaboration ongoing for development of IVD to support PET brain amyloid imaging of early Alzheimers Disease
- DiaGenic awarded international award for best R&D contribution in 2011 and receives NOK 7.8 million from Norwegian Research Council
- License discussions and R&D collaborative efforts ongoing – US and EU regulatory path outlined
- Additional patent received (BCtect in Japan) and completion of trademark process for ADtect®, BCtect®, PDtect® MCItect®
- Financials
- Outlook and Summary

- **New CEO in DiaGenic – Paul de Potocki appointed - change of management September 17th**

Paul de Potocki
New CEO in DiaGenic ASA

Summary :

- Previous CEO of Aerocrine AB - a medical device and diagnostic company pioneering a novel technology for the improved diagnosis and management of asthma.
- Senior Vice President, Commercial and Strategic Development at Biovitrum AB.
- Executive Vice President, Strategic Marketing at the German company Fresenius Kabi
- Divisional Vice President, Global Sales and Strategic Marketing with Pharmacia.
- International commercial management positions within the Unilever group.

Strengthening of the Board of Directors DiaGenic ASA

- New Board member, Patrik Dahlen, CEO , Immunodiagnostic Systems Holdings plc, appointed Deputy Chairman of the Board
- Ingrid Wiik, Ulrica Slåne and Tom Pike reelected to the Board
- Henrik Lund reelected as Chairman of the board, 17th September
- Board and management strengthened with diagnostic company expertise

Henrik Lund
Chairman
(Acting CEO)

Patrik Dahlen

Deputy
Chairman

Ingrid Wiik

Acting
Chairman



Ulrica Slåne
BoD member

Tom Pike
BoD member



Main event (post Q2): New version of ADtect shows improved accuracy - 82% - a significant milestone in product development – results from AAIC July 18th

Q2 2012 highlight (post Q): IAAC Vancouver July 18th

R&D excellence and continuous product improvement
- new DiaGenic study finds improved accuracy > 80% for early Alzheimer detection



Summary of findings of new DiaGenic study demonstrating >80% accuracy – using fewer genes

- New ADtect using only 20 genes shows improved accuracy versus current version (ADtect 72%, **new ADtect 82%**)
- Further development of **MCItect** also finds improved accuracy in detecting MCI that converts to AD dementia (previous 20 gene signature 70-74%, **new 25 gene signature 81%**)
- Two major advancements:
  - Improved accuracy
  - Fewer genes in new signatures
- New technology (Applied Biosystems, ViiA 7) and improvements in algorithms underlie the new finings.

Implications of new findings – target threshold passed

- Target threshold of >80% diagnostic and predictive accuracy has been passed – much better applicability in clinical setting
- Fewer genes in new versions of ADtect and in MCItect means transfer to other technological platforms is much easier



Neurobiology of Aging, Vol. 19, No. 2, pp. 109–116, 1998

0197-4580/98 $19.00 + .00

ELSEVIER

PII:S0197-4580(98)00022-0

Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease"

THE RONALD AND NANCY REAGAN RESEARCH INSTITUTE OF THE ALZHEIMER'S ASSOCIATION AND THE NATIONAL INSTITUTE ON AGING WORKING GROUP[1,2,3]

The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association, Chicago, IL and the National Institute on Aging, Bethesda, MD

The ideal biomarker for Alzheimer's disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically-confirmed cases; it should have a sensitivity >80% for detecting AD and a specificity of >80% for distinguishing other dementias; it should be reliable, reproducible, non-invasive, simple to perform, and inexpensive. Recommended steps to establish a biomarker include confirmation by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. Our review of current candidate markers indicates that for suspected early-onset familial AD, it is appropriate to search for mutations in the presenilin 1, presenilin 2, and amyloid precursor protein genes. Individuals with these mutations typically have increased levels of the amyloid $A\beta_{42}$ peptide in plasma and decreased levels of APPs in cerebrospinal fluid. In late-onset and sporadic AD, these measures are not useful, but detecting an apolipoprotein E e4 allele can add confidence to the clinical diagnosis. Among the other proposed molecular and biochemical markers for sporadic AD, cerebrospinal fluid assays showing low levels of $A\beta_{42}$ and high levels of tau come closest to fulfilling criteria for a useful biomarker. © 1998 Elsevier Science Inc.

THE Working Group on Molecular and Biochemical Markers of Alzheimer's Disease was convened to examine the relative merits of biological markers proposed for the early diagnosis of Alzheimer's disease (AD). At present, diagnosing AD and distinguishing it from other dementias depend primarily on clinical evaluation, and ultimately on clinical judgment. Based on this approach, a great deal has been learned about the genetics, age of onset, duration, clinical course, neurological and psychiatric manifestations, and neuropathology of AD. However, there are still many scientific issues that need to be resolved in order to improve the accuracy, sensitivity, reliability, and validity of biochemical and molecular diagnostic measures. Fifty-five invitations were sent and thirty position papers were submitted. The titles, authors, and their affiliations are noted in Appendix I. Their contributions reflect the diverse perspectives among the international community of investigators engaged in research on the diagnosis of AD. In September 1997, the Advisory Committee of the Working Group (the Appen-

Q2 update Diagenic GE Healthcare Collaboration (1)

- *First patient included (FPI) in the study June 7th 2012 – Clinical phase initiated*
- *2,5 months from* March 27th 2012 *signing with GE Healthcare to FPI - rapid initiation of clinical phase*
- *Target recruitment is 150 patients will undergo 18F-Flutemetamol amyloid-PET imaging (GE Healthcare) combined with exploratory gene expression analyses (DiaGenic).*
- *Final results 2015.*



DIAGENIC

Press Room | Releases | Multimedia | About

First patient included in DiaGenic and GE Healthcare project to develop a blood test for Mild Cognitive Impairment, associated with Alzheimer's

7 Jun, 2012 17:28 CET

Oslo – June 7th 2012: DiaGenic ASA [OSL:DIAG] today announced that the first patient with MCI (Mild Cognitive Impairment) was examined with [18F] Flutemetamol PET imaging at University of Lund Sweden in the DiaGenic and GE Healthcare Research Collaboration announced March 27th 2012. First patient examined with PET imaging means that the clinical phase of the collaboration has been initiated.

The study aims to develop a blood-based gene expression profile in patients with mild cognitive impairment (MCI) to be used in conjunction with PET imaging of the brain. The PET imaging agent, [18F] Flutemetamol, is currently in phase 3 development and is not yet approved by any regulatory authority.



DIAGENIC

Press Room | Releases | Multimedia | About

DiaGenic and GE Healthcare to develop blood-based test for mild cognitive impairment, a disorder associated with risk for Alzheimer's Disease

26 Mar, 2012 16:05 CET

Oslo – March 26th 2012: DiaGenic ASA [OSL:DIAG] today announced a research agreement to collaborate with GE Healthcare to develop a blood-based test using DiaGenic's peripheral gene expression profiling in patients with mild cognitive impairment, a disorder associated with risk for Alzheimer's Disease. The study would be used in conjunction with PET imaging to identify a blood based gene expression signature in these patients. The PET imaging agent, [18F] Flutemetamol, is currently in phase 3 development and is not yet approved by any regulatory authority.

This research effort will combine expertise in data integration, informatics, genomics and imaging. Its goal will be to find a signature that may identify subjects at risk of Alzheimer's at a very early disease stage. The collaboration is part of a broad portfolio of diagnostic solutions that GE Healthcare is developing in the Alzheimer's field.

Q2 update Diagenic GE Healthcare Collaboration (2)

- *R&D agreement for first in class study comparing gene signature and brain PET imaging.*
- *GE Healthcare completes successful phase III with autopsy studies and restates FDA filing end of 2012*
- *Alzheimer market see important change with FDA approval of first 18 F-PET ligand (AMYVID®; Eli Lilly) for detecting amyloid in the brain April 4th . Market expected to hit 1.5 BUSD.*
- *Amyloid PET launch in selected US sites from June 1st onwards*
- *DiaGenic and GE Healthcare to develop a selection tool for their PET ligand 18F-Flutemetamol.*



DIAGENIC

Press Room | Releases | Multimedia | About

First patient included in DiaGenic and GE Healthcare project to develop a blood test for Mild Cognitive Impairment, associated with Alzheimer's

7 Jun, 2012 17:28 CET

Oslo – June 7th 2012: DiaGenic ASA [OSL:DIAG] today announced that the first patient with MCI (Mild Cognitive Impairment) was examined with [18F] Flutemetamol PET imaging at University of Lund Sweden in the DiaGenic and GE Healthcare Research Collaboration announced March 27th 2012. First patient examined with PET imaging means that the clinical phase of the collaboration has been initiated.

The study aims to develop a blood-based gene expression profile in patients with mild cognitive impairment (MCI) to be used in conjunction with PET imaging of the brain. The PET imaging agent, [18F] Flutemetamol, is currently in phase 3 development and is not yet approved by any regulatory authority.

DIAGENIC

Press Room | Releases | Multimedia | About

DiaGenic and GE Healthcare to develop blood-based test for mild cognitive impairment, a disorder associated with risk for Alzheimer's Disease

26 Mar, 2012 16:05 CET

Oslo – March 26th 2012: DiaGenic ASA [OSL:DIAG] today announced a research agreement to collaborate with GE Healthcare to develop a blood-based test using DiaGenic's peripheral gene expression profiling in patients with mild cognitive impairment, a disorder associated with risk for Alzheimer's Disease. The study would be used in conjunction with PET imaging to identify a blood based gene expression signature in these patients. The PET imaging agent, [18F] Flutemetamol, is currently in phase 3 development and is not yet approved by any regulatory authority.

This research effort will combine expertise in data integration, informatics, genomics and imaging. Its goal will be to find a signature that may identify subjects at risk of Alzheimer's at a very early disease stage. The collaboration is part of a broad portfolio of diagnostic solutions that GE Healthcare is developing in the Alzheimer's field.

Update on Parkinson Disease (PD)
Completion of clinical phase of Familial PD study – results expected in Q3

- *DiaGenic presented high accuracy (88%) in diagnosing early disease in European multicenter trial (Q1)*
- *To date, there are few alternatives for differential diagnosis of PD and DiaGenic may offer innovative solutions.*

Pending board meeting

DIAGENIC

Press Room | Releases | Multimedia | About

DiaGenic reports high 85% accuracy for blood based diagnosis in early Parkinson patients in European multicenter study

8 Feb, 2012 17:28 CET

The initial findings from DiaGenic sponsored prospective European multicenter Parkinson study is reported. The initial read out of the first subcohort of 79 PD patients and 75 matched healthy controls with no neurodegenerative disease, shows a diagnostic accuracy of 85% in early disease patients while overall accuracy was 88% across all stages.

The preliminary results of the biomarker development program in Parkinsons's Disease (PD) were presented at the 19th World Congress on Parkinson's Disease and Related Disorders in Shanghai in November last year. DiaGenic reported that their gene expression data contained information that can be used to classify PD with high average accuracy in peripheral blood.

DIAGENIC

Press Room | Releases | Multimedia | About

DiaGenic reports completion of data collection and genetic analyses in a unique study on familial Parkinson's disease

8 May, 2012 09:40 CET

Oslo – May 8th 2012 (DiaGenic ASA [OSL:DIAG]): DiaGenic today reports on the finalization of data collection and database lock of a blinded study in a Norwegian cohort of 80 patients with familial Parkinson's disease (PD). The majority of these patients are carrying a mutation in the parkin 8 gene (also called LRRK2) that significantly increases the risk of developing PD. Patients recruited from St Olavs University Hospital under the lead of Principal Investigator Professor Jan Aasly are all LRRK2 mutation carriers with or without the disease or healthy relatives. Unblinding of the study is set to the May 16th and analysis and reporting is expected to be completed during summer 2012.

Q2 update on US out-licensing and Pharma partnering

Progress in out-licensing activities in the US

Additional large pharma collaboration requests for DiaGenic's Alzheimer platform/products

- *DiaGenic AD and PD technology in focus.*
- *Counterparties represent service providers (typically laboratory chains) or technology providers (platform providers).*
- *Scope for license is market access through US PMA/510k approval, milestone based upfront and royalty on commercialization.*
- *DiaGenic continue discussions to add pharma R&D collaborations with partners having phase II-III clinical programs with NCEs.*

Q2 update: Alzheimer Pharma Market update

- Pfizer, JnJ's bapineuzumab and Eli Lilly's solanezumab did not reach phase III endpoints. All program i.v. bapi programs closing. Eli Lilly continue
- *Early intervention key - MCI and early diagnosis even more important*
- *No immediate fall-out on development programs for Companies targeting MCI or that have non-amyloid approaches in phase II-III.*
- *Roche, BMS and EnVivo have indicated they will continue with their late stage programs*
- Solanezumab *phase III pooled results suggests slowing of cognitive decline in mild dementia – open study extension*

Q2 update: Additional patent received (Japan; for breast cancer) and completion of trademark process for ADtect®, BCtect®, PDtect® MCItect®

- *Breast cancer Family 3 patent in Japan granted*
- *Trademark registration completed. Trademark for MCItect in South Korea added*
- *US, Europe, RoW trademark coverage*

Pending board meeting

DIAGENIC

Press Room | Releases | Multimedia | About

DiaGenic has been granted world-wide trademarks for its key brands ADtect®, BCtect®, PDtect® and MCItect®

8 May, 2012 13:00 CET

Oslo – May 8th 2012: DiaGenic ASA [OSL:DIAG] have received grants of world-wide trademark for key brand names in the DiaGenic portfolio: ADtect®, MCItect®, PDtect® and BCtect®. Trademark protection adds to building a strong portfolio of intellectual properties (IP) for product commercialization.

DiaGenic has today reviewed its trademark coverage in mayor markets. Broad coverage in most key markets for ADtect, PDtect, MCItect and BCtect have been obtained. Registered trademarks are now granted in 30 countries representing key global markets including US, EU and Rest of the World (ROW). For one product, BCtect®, a preliminary refusal of trademark in the US, due to similarity with "BC detect" from Panacea Inc., is noted. MCItect® application in South Korea is still pending processing. For more information see a.o. WIPO, World Intellectual Property Organisation.

DIAGENIC

Press Room | Releases | Multimedia | About

Notice of allowance of Breast Cancer Patent in Japan

3 Aug, 2012 08:30 CET

DiaGenic has received notice of allowance of the family 3 patent application in Japan (2007-514130). The claims allowed cover the use of some important gene sequences in blood sample for detection and monitoring of breast cancer. The patent will be valid until 2025. Family 3 patents have earlier been granted in US and Europe.

"The new Japanese patent is an important milestone which strengthens our position in Asia. The company will now have a broad patent protection in Japan, one of the largest economies in the world" said DiaGenic CEO Henrik Lund MD PhD.

Q2 update: DiaGenic receives international award for best R&D publication in 2011 and receive NOK 7.8 million from Norwegian Research Council

- *Best scientific publication in 2011 in Journal of Alzheimer's Disease*
- *Development work on ADtect awarded*
- *Scientific credibility of DiaGenic technology strengthened*
- *Norwegian Research Council awards NOK 7.8 million to RNA program. Collaboration with Norwegian biobank (HUNT)*

Pending board meeting

DIAGENIC

Press Room | Releases | Multimedia | About

DiaGenic awarded research grant of NOK 7.8 million for further development of DiaGenics tests for early detection of Alzheimer's disease

15 May, 2012 15:53 CET

DiaGenic has been granted NOK 7.8 million of the Norwegian Research Council's BIA funds. The funds will be employed in an industry-oriented research project to improve robustness and reduce costs of procedure in blood based diagnostics of Alzheimer's disease. The clinical samples will be sourced from DiaGenic's biobank as well as the HUNT Biosciences biobank.

The grant announcement for the project "Blood microRNAs for the early diagnosis of Alzheimer's disease" was made public today by the Research Council of Norway and is conditional upon signature by the parties.

"Norwegian Research Council has in the past contributed with significant funding for DiaGenic's development of diagnostic tests. This new grant for development of blood based diagnostics for early Alzheimer's disease represents an important financial contribution", says CEO in DiaGenic, MD PhD Henrik Lund.

DIAGENIC

Press Room | Releases | Multimedia | About

DiaGenic awarded for best article in 2011

2 May, 2012 15:00 CET

DiaGenic Press release JAD award 2012Highly ranked Journal of Alzheimer's Disease (JAD) today announced that Anders Lönneborg and DiaGenic has been chosen as recipient of the 2011 Alzheimer Award. The article «A Novel Blood Test for the Early Detection of Alzheimer's Disease" which covers the development of the diagnostic Alzheimer test ADtect® was voted for by a majority of the Associate Editors of JAD as the most outstanding article in 2011. This prestigious award is supported by IOS Press and Elan Pharmaceuticals.

"Journal of Alzheimer's Disease is a highly recognised journal in the Alzheimer's disease field. The award provides further recognition from leading experts to the development of DiaGenic's Alzheimer test ADtect®", says Magnus Sjögren MD PhD, CMO of DiaGenic.

2nd quarter 2012 financials



Finance, Profit & Loss

P&L 2Q
(thousand NOK)

	2Q '12	2Q '11
Revenue	42	1,151
Grants	1,015	926
Operating Cost net of Grants	12,726	9,829
Operating loss	(12,685)	(8,670)
Net finance	231	603
Net income	(12,454)	(8,067)

Operating Cost
(thousand NOK)



	Q2 11	Q3 11	Q4 11	Q1 12	Q2 12
Cost of sales	951	133	245	320	110
Salaries and related	4 787	5 808	6 872	5 959	7 410
Depreciation and Write downs	239	261	222	224	225
Other operating cost	3 844	3 542	2 036	2 922	4 980

Finance,
Cash position and outlook



- Cash balance end of June 2012: NOK 39 million
- No significant changes in cost level expected for 2012 compared with 2011
- Explore financing opportunities through proceeds from up-front payments on out-licensing or through other options such as loans, equity and R&D grants

Outlook



Goals for next 12 months

- Initiation of clinical trials in the US to prepare FDA submission for MCItect
- CE marking of MCItect and new ADtect in Europe
- Partner agreements with leading pharmaceutical companies with ongoing clinical programs in Alzheimer's disease
- Presentation of results from Parkinson LRRK2 study
- Presentation of interim results from the ongoing PET study with GE Healthcare for amyloid IVD development
- Explore financing opportunities through proceeds from up-front payments on out-licensing or through other options such as loans, equity and R&D grants

DiaGenic

DiaGenic ASA
Grenseveien 92, N-0663 Oslo, Norway
Tel +47 23 24 89 50
Mail: diagenic@diagenic.com
www.diagenic.com